104 related articles for article (PubMed ID: 25046396)
1. Optic coherence tomography of foveal hemorrhage associated with chronic myelogenous leukemia.
Hori S; Yamamoto K
Retina; 2015 Mar; 35(3):597-9. PubMed ID: 25046396
[No Abstract] [Full Text] [Related]
2. Leukemic retinopathy and foveal infiltrates.
Kumar V; Kumawat D; Dhakal S
Int Ophthalmol; 2018 Jun; 38(3):1301-1303. PubMed ID: 28527028
[TBL] [Abstract][Full Text] [Related]
3. Chronic myelogenous leukemia presenting with bilateral optic disc neovascularization.
Almeida DR; Chin EK; Grant LW
Can J Ophthalmol; 2014 Jun; 49(3):e68-70. PubMed ID: 24862787
[No Abstract] [Full Text] [Related]
4. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. Optical coherence tomography findings in occult macular dystrophy.
Brockhurst RJ; Sandberg MA
Am J Ophthalmol; 2007 Mar; 143(3):516-8. PubMed ID: 17317401
[TBL] [Abstract][Full Text] [Related]
7. [Sudden bilateral decreased vision in a 14-year-old boy].
Marx S; Scheuerle A; Khoramnia R; Tandogan T; Kaiser D; Auffarth GU; Sel S
Ophthalmologe; 2017 Aug; 114(8):748-750. PubMed ID: 28138752
[No Abstract] [Full Text] [Related]
8. Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
Bajel A; Bassili S; Seymour JF
Leuk Res; 2008 Nov; 32(11):1789-90. PubMed ID: 18462793
[No Abstract] [Full Text] [Related]
9. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?
Breccia M; Cannella L; Stefanizzi C; Carotti A; Santopietro M; Alimena G
Bone Marrow Transplant; 2009 Sep; 44(5):331-2. PubMed ID: 19219075
[No Abstract] [Full Text] [Related]
10. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M
Lancet Oncol; 2007 Mar; 8(3):273-4. PubMed ID: 17329198
[No Abstract] [Full Text] [Related]
11. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
[No Abstract] [Full Text] [Related]
12. Dasatinib: for some difficult cases of adult leukaemia.
Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
[No Abstract] [Full Text] [Related]
13. Dasatinib (Sprycel) for CML and Ph + ALL.
Med Lett Drugs Ther; 2007 Jan; 49(1252):6-7. PubMed ID: 17220814
[No Abstract] [Full Text] [Related]
14. Bringing prognostic scores for chronic myeloid leukemia patients up to date.
Breccia M; Alimena G
Expert Rev Hematol; 2011 Aug; 4(4):373-5. PubMed ID: 21801127
[No Abstract] [Full Text] [Related]
15. Dasatinib.
Kantarjian H; Jabbour E; Grimley J; Kirkpatrick P
Nat Rev Drug Discov; 2006 Sep; 5(9):717-8. PubMed ID: 17001803
[No Abstract] [Full Text] [Related]
16. The Authors Respond.
Landsman-Blumberg PB
J Manag Care Spec Pharm; 2015 Nov; 21(11):1089. PubMed ID: 26829824
[No Abstract] [Full Text] [Related]
17. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
[No Abstract] [Full Text] [Related]
18. [Thickening or hypoplasia of the fovea].
Nessmann A; Schramm C; Gelisken F
Ophthalmologe; 2016 Jun; 113(6):507-10. PubMed ID: 26242851
[TBL] [Abstract][Full Text] [Related]
19. Management of Bcr-Abl-positive leukemias with dasatinib.
Hochhaus A
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
[TBL] [Abstract][Full Text] [Related]
20. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
Caocci G; Atzeni S; Orrù N; Azzena L; Martorana L; Littera R; Ledda A; La Nasa G
Leukemia; 2008 Nov; 22(11):2127-8. PubMed ID: 18463676
[No Abstract] [Full Text] [Related]
[Next] [New Search]
